Who are ANAVEX2-73 Intravenous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GP40081, AXS-02.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anavex2-73-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ANAVEX2-73 Intravenous — Competitive Intelligence Brief

ANAVEX2-73 Intravenous (ANAVEX2-73 Intravenous) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sigma-1 receptor modulator. Area: Neurology.

phase 2 Sigma-1 receptor modulator Sigma-1 receptor, Muscarinic acetylcholine receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ANAVEX2-73 Intravenous (ANAVEX2-73 Intravenous) — Anavex Life Sciences Corp.. ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ANAVEX2-73 Intravenous TARGET	ANAVEX2-73 Intravenous	Anavex Life Sciences Corp.	phase 2	Sigma-1 receptor modulator	Sigma-1 receptor, Muscarinic acetylcholine receptor
GP40081	GP40081	Geropharm	phase 3	sigma-1 receptor modulator	sigma-1 receptor
AXS-02	AXS-02	Axsome Therapeutics, Inc.	phase 3	NMDA receptor antagonist / Sigma-1 receptor modulator combination	NMDA receptor, Sigma-1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sigma-1 receptor modulator class)

Anavex Life Sciences Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANAVEX2-73 Intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/anavex2-73-intravenous. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab